- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human Immunodeficiency virus (HIV)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1504KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 385KB)
Cabotegravir/cabotegravir and rilpivirine – March 2021
Cabotegravir and rilpivirine: Pack containing 1 injection of cabotegravir 600 mg in 3 mL and 1 injection of rilpivirine 900 mg in 3mL; Cabenuva®
Last updated
16 July 2021